ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Amgen and Novartis present new data demonstrating long-term efficacy, safety and tolerability of Aimovig TM (erenumab-aooe) in patients with chronic and episodic migraine
July 05, 2018Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of AimovigTM (erenumab-aooe) in patients with chronic and episodic migraine, respectively -
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in epis
January 23, 2018The study met its primary endpoint, with significantly more patients taking erenumab experiencing at least a 50% reduction from baseline in their monthly migraine days as compared to placebo.
Pharma Sources Insight January 2025
